Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector

Area of Science:

• Gene therapy
• Retroviral vector development
• Molecular biology

Background:

• Adenosine deaminase (ADA) deficiency causes severe combined immunodeficiency.
• Retroviral vectors are used for gene delivery in gene therapy.
• Enhancers can modulate gene expression from retroviral vectors.

Purpose of the Study:

• To assess the efficacy of two novel retroviral vectors with lymphoid-specific enhancers for human adenosine deaminase (hADA) expression.
• To compare the expression levels of hADA mediated by modified vectors versus a basic retroviral vector.
• To evaluate long-term hADA expression in vivo following bone marrow transplantation.

Main Methods:

• Construction and characterization of two retroviral vectors: delta N2TADA (with T-cell receptor enhancer) and delta N2 mu ADA (with immunoglobulin enhancer).
• Transduction of hADA into murine fibroblast and myeloma cells in culture.
• Bone marrow transplantation in mice followed by analysis of hADA expression in various cell lineages.

Main Results:

• Both novel retroviral vectors efficiently transduced hADA into cultured cells.
• No significant quantitative difference in hADA expression was observed between the modified vectors and the basic delta N2ADA vector.
• Long-term expression (4-8 months) of hADA was achieved in lymphoid, myeloid, and erythroid cells of transplanted mice with all three vectors.

Conclusions:

• Lymphoid-specific enhancers did not significantly improve hADA expression levels compared to the basic retroviral vector.
• The tested retroviral vectors demonstrate potential for sustained gene expression in hematopoietic stem cells post-transplantation.
• Further optimization of enhancer elements may be necessary for achieving higher therapeutic levels of hADA expression.